文献速递前列腺癌

基因表达分类器检测对根治性前列腺切除术后辅助治疗的影响:G-MINOR前瞻性随机整群交叉试验

Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.
PubMed 文献 · Eur Urol · 2024-10-08

G-MINOR前瞻性随机整群交叉试验评估Decipher基因表达分类器(GC)对根治性前列腺切除术后辅助治疗的影响。175例患者进入GC组27个周期,163例进入常规护理组28个周期。术后18个月辅助治疗率GC组9.7% vs 常规护理组8.7%(平均差异0.99%,95%CI -7.6%~9.6%,p=0.8);按GC风险分组,高GC风险相比低GC评分辅助治疗比值比OR=6.9(95%CI 1.8~26,p=0.005)。

要点

  • GC检测组与常规护理组术后18个月辅助治疗率无显著差异(9.7% vs 8.7%,p=0.8)。
  • 按GC风险分组,高GC风险相比低GC评分辅助治疗比值比OR=6.9(95%CI 1.8~26,p=0.005)。
  • GC评分每增加0.1辅助治疗比值比OR=1.35(95%CI 0.98~1.85,p=0.066),未达统计学显著。

核心结论

  • 从患者报告呈现的风险类别看,GC检测影响辅助治疗的实施。
  • 这些数据并不为在辅助治疗场景中使用GC检测提供具体支持。
  • 因肿瘤学结局尚不成熟,现有数据无法回答GC检测是否带来任何肿瘤控制获益。

研究设计与样本

  • 前瞻性随机整群交叉试验,纳入根治性前列腺切除术后9个月内、pT3-4期和/或手术切缘阳性、前列腺特异性抗原<0.1 ng/ml的患者。
  • 中心被随机分配至3个月周期的GC指导诊疗或常规护理序列,所有周期均向治疗医生和患者提供CAPRA-S复发风险评分。
  • GC组共175例患者进入27个周期,常规护理组共163例患者进入28个周期。
  • 比较GC检测结果对辅助治疗的影响与单纯常规护理,并评估患者报告的泌尿和性功能纵向变化。

主要发现

  • 术后18个月,GC组平均患者接受辅助治疗的比例为9.7%,常规护理组为8.7%(平均差异0.99%,95%CI -7.6%~9.6%,p=0.8)。
  • 控制CAPRA-S评分后,GC评分每增加0.1,辅助治疗比值比OR=1.35(95%CI 0.98~1.85,p=0.066),未达统计学显著。
  • 按反映临床使用的GC风险分组,控制CAPRA-S评分后,高GC风险相比低GC评分接受辅助治疗的比值比OR=6.9(95%CI 1.8~26,p=0.005)。
  • 研究组间患者报告的泌尿和性功能无差异。

临床怎么用

  • 原文结论指出,从患者报告呈现的风险类别看,GC检测影响辅助治疗的实施。
  • 原文结论指出,这些数据并不为在辅助治疗场景中使用GC检测提供具体支持。
  • 原文结论指出,因肿瘤学结局尚不成熟,现有数据无法回答GC检测是否带来任何肿瘤控制获益。

局限性

  • 肿瘤学结局尚不成熟,现有数据无法回答GC检测是否带来任何肿瘤控制获益。
  • GC评分每增加0.1与辅助治疗的关联未达统计学显著(OR=1.35,95%CI 0.98~1.85,p=0.066)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Decipher is a tissue-based genomic classifier (GC) developed and validated in the post-radical prostatectomy (RP) setting as a predictor of metastasis. We conducted a prospective randomized controlled cluster-crossover trial assessing the use of Decipher to determine its impact on adjuvant treatment after RP. METHODS: Eligible patients had undergone RP within 9 mo of enrollment, had pT3-4 disease and/or positive surgical margins, and prostate-specific antigen <0.1 ng/ml. Centers were randomized to a sequence of 3-mo periods of either GC-informed care or usual care (UC). Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) recurrence risk scores were provided to treating physicians and patients in all periods. KEY FINDINGS AND LIMITATIONS: Impact of GC test results on adjuvant treatment were compared with UC alone. Longitudinal patient-reported urinary and sexual function was assessed. A total of 175 patients were enrolled in 27 periods with GC and 163 in 28 periods with UC. At 18 mo after RP, an average patient in the GC arm received adjuvant treatment 9.7% of the time compared with 8.7% for an average individual in the UC arm (0.99% mean difference, 95% confidence interval [CI] -7.6%, 9.6%, p = 0.8). While controlling for CAPRA-S score, higher GC scores tended to result in an increased likelihood of adjuvant treatment that was not statistically significant (odds ratio [OR] = 1.35 per 0.1 increase in GC score, 95% CI 0.98-1.85, p = 0.066). Using the GC risk groups, reflecting clinical use, a high GC risk was associated with significantly higher odds of receiving adjuvant treatment (OR = 6.9, 95% CI 1.8, 26, p = 0.005) compared with a low GC score, adjusted for CAPRA-S score. There were no differences in patient-reported urinary and sexual function between the study arms. As oncologic outcomes are immature, the present data cannot address whether GC testing provides any cancer control benefit. CONCLUSIONS AND CLINICAL IMPLICATIONS: GC testing impacts adjuvant therapy administration when viewed through the risk categories presented in the patient report; however, these data do not provide specific support for GC testing in the adjuvant treatment setting.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Morgan TM, Daignault-Newton S, Spratt DE, et al. Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial. Eur Urol. 2024. PMID: 39379238. doi:10.1016/j.eururo.2024.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。